IRE1α-XBP1s pathway promotes prostate cancer by activating c-MYC signaling

Sheng X, Nenseth HZ, Qu S, Kuzu OF, Frahnow T, Simon L, Greene S, Zeng Q, Fazli L, Rennie PS, Mills IG, et al. (2019)
Nature Communications 10(1): 323 (2019) .

Download
Es wurde kein Volltext hochgeladen. Nur Publikationsnachweis!
Zeitschriftenaufsatz | Veröffentlicht | Englisch
Autor
; ; ; ; ; ; ; ; ; ; ;
Alle
Erscheinungsjahr
Zeitschriftentitel
Nature Communications
Band
10
Ausgabe
1
Art.-Nr.
323 (2019)
eISSN
PUB-ID

Zitieren

Sheng X, Nenseth HZ, Qu S, et al. IRE1α-XBP1s pathway promotes prostate cancer by activating c-MYC signaling. Nature Communications. 2019;10(1): 323 (2019) .
Sheng, X., Nenseth, H. Z., Qu, S., Kuzu, O. F., Frahnow, T., Simon, L., Greene, S., et al. (2019). IRE1α-XBP1s pathway promotes prostate cancer by activating c-MYC signaling. Nature Communications, 10(1), 323 (2019) . doi:10.1038/s41467-018-08152-3
Sheng, X., Nenseth, H. Z., Qu, S., Kuzu, O. F., Frahnow, T., Simon, L., Greene, S., Zeng, Q., Fazli, L., Rennie, P. S., et al. (2019). IRE1α-XBP1s pathway promotes prostate cancer by activating c-MYC signaling. Nature Communications 10:323 (2019) .
Sheng, X., et al., 2019. IRE1α-XBP1s pathway promotes prostate cancer by activating c-MYC signaling. Nature Communications, 10(1): 323 (2019) .
X. Sheng, et al., “IRE1α-XBP1s pathway promotes prostate cancer by activating c-MYC signaling”, Nature Communications, vol. 10, 2019, : 323 (2019) .
Sheng, X., Nenseth, H.Z., Qu, S., Kuzu, O.F., Frahnow, T., Simon, L., Greene, S., Zeng, Q., Fazli, L., Rennie, P.S., Mills, I.G., Danielsen, H., Theis, F., Patterson, J.B., Jin, Y., Saatcioglu, F.: IRE1α-XBP1s pathway promotes prostate cancer by activating c-MYC signaling. Nature Communications. 10, : 323 (2019) (2019).
Sheng, Xia, Nenseth, Hatice Zeynep, Qu, Su, Kuzu, Omer F., Frahnow, Turid, Simon, Lukas, Greene, Stephanie, Zeng, Qingping, Fazli, Ladan, Rennie, Paul S., Mills, Ian G., Danielsen, Håvard, Theis, Fabian, Patterson, John B., Jin, Yang, and Saatcioglu, Fahri. “IRE1α-XBP1s pathway promotes prostate cancer by activating c-MYC signaling”. Nature Communications 10.1 (2019): 323 (2019) .
Link(s) zu Volltext(en)
Access Level
Restricted Closed Access

53 References

Daten bereitgestellt von Europe PubMed Central.

Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer.
Watson PA, Arora VK, Sawyers CL., Nat. Rev. Cancer 15(12), 2015
PMID: 26563462
Divergent androgen regulation of unfolded protein response pathways drives prostate cancer.
Sheng X, Arnoldussen YJ, Storm M, Tesikova M, Nenseth HZ, Zhao S, Fazli L, Rennie P, Risberg B, Wæhre H, Danielsen H, Mills IG, Jin Y, Hotamisligil G, Saatcioglu F., EMBO Mol Med 7(6), 2015
PMID: 25864123
MYC, Metabolism, and Cancer.
Stine ZE, Walton ZE, Altman BJ, Hsieh AL, Dang CV., Cancer Discov 5(10), 2015
PMID: 26382145
MYC and Prostate Cancer.
Koh CM, Bieberich CJ, Dang CV, Nelson WG, Yegnasubramanian S, De Marzo AM., Genes Cancer 1(6), 2010
PMID: 21779461
Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma.
Mimura N, Fulciniti M, Gorgun G, Tai YT, Cirstea D, Santo L, Hu Y, Fabre C, Minami J, Ohguchi H, Kiziltepe T, Ikeda H, Kawano Y, French M, Blumenthal M, Tam V, Kertesz NL, Malyankar UM, Hokenson M, Pham T, Zeng Q, Patterson JB, Richardson PG, Munshi NC, Anderson KC., Blood 119(24), 2012
PMID: 22538852
Structure and mechanism of action of the hydroxy-aryl-aldehyde class of IRE1 endoribonuclease inhibitors.
Sanches M, Duffy NM, Talukdar M, Thevakumaran N, Chiovitti D, Canny MD, Lee K, Kurinov I, Uehling D, Al-awar R, Poda G, Prakesch M, Wilson B, Tam V, Schweitzer C, Toro A, Lucas JL, Vuga D, Lehmann L, Durocher D, Zeng Q, Patterson JB, Sicheri F., Nat Commun 5(), 2014
PMID: 25164867
Potent and selective inhibitors of the inositol-requiring enzyme 1 endoribonuclease.
Volkmann K, Lucas JL, Vuga D, Wang X, Brumm D, Stiles C, Kriebel D, Der-Sarkissian A, Krishnan K, Schweitzer C, Liu Z, Malyankar UM, Chiovitti D, Canny M, Durocher D, Sicheri F, Patterson JB., J. Biol. Chem. 286(14), 2011
PMID: 21303903
c-Myc Antagonises the Transcriptional Activity of the Androgen Receptor in Prostate Cancer Affecting Key Gene Networks.
Barfeld SJ, Urbanucci A, Itkonen HM, Fazli L, Hicks JL, Thiede B, Rennie PS, Yegnasubramanian S, DeMarzo AM, Mills IG., EBioMedicine 18(), 2017
PMID: 28412251
Unbiased Prediction and Feature Selection in High-Dimensional Survival Regression.
Laimighofer M, Krumsiek J, Buettner F, Theis FJ., J. Comput. Biol. 23(4), 2016
PMID: 26894327
Inhibition of ER stress-associated IRE-1/XBP-1 pathway reduces leukemic cell survival.
Tang CH, Ranatunga S, Kriss CL, Cubitt CL, Tao J, Pinilla-Ibarz JA, Del Valle JR, Hu CC., J. Clin. Invest. 124(6), 2014
PMID: 24812669
XBP1 promotes triple-negative breast cancer by controlling the HIF1α pathway.
Chen X, Iliopoulos D, Zhang Q, Tang Q, Greenblatt MB, Hatziapostolou M, Lim E, Tam WL, Ni M, Chen Y, Mai J, Shen H, Hu DZ, Adoro S, Hu B, Song M, Tan C, Landis MD, Ferrari M, Shin SJ, Brown M, Chang JC, Liu XS, Glimcher LH., Nature 508(7494), 2014
PMID: 24670641
ER Stress Sensor XBP1 Controls Anti-tumor Immunity by Disrupting Dendritic Cell Homeostasis.
Cubillos-Ruiz JR, Silberman PC, Rutkowski MR, Chopra S, Perales-Puchalt A, Song M, Zhang S, Bettigole SE, Gupta D, Holcomb K, Ellenson LH, Caputo T, Lee AH, Conejo-Garcia JR, Glimcher LH., Cell 161(7), 2015
PMID: 26073941
p58(IPK)-mediated attenuation of the proapoptotic PERK-CHOP pathway allows malignant progression upon low glucose.
Huber AL, Lebeau J, Guillaumot P, Petrilli V, Malek M, Chilloux J, Fauvet F, Payen L, Kfoury A, Renno T, Chevet E, Manie SN., Mol. Cell 49(6), 2013
PMID: 23395000
Sequencing of agents in castration-resistant prostate cancer.
Lorente D, Mateo J, Perez-Lopez R, de Bono JS, Attard G., Lancet Oncol. 16(6), 2015
PMID: 26065613
ER stress-mediated autophagy promotes Myc-dependent transformation and tumor growth.
Hart LS, Cunningham JT, Datta T, Dey S, Tameire F, Lehman SL, Qiu B, Zhang H, Cerniglia G, Bi M, Li Y, Gao Y, Liu H, Li C, Maity A, Thomas-Tikhonenko A, Perl AE, Koong A, Fuchs SY, Diehl JA, Mills IG, Ruggero D, Koumenis C., J. Clin. Invest. 122(12), 2012
PMID: 23143306
Characterization of a novel PERK kinase inhibitor with antitumor and antiangiogenic activity.
Atkins C, Liu Q, Minthorn E, Zhang SY, Figueroa DJ, Moss K, Stanley TB, Sanders B, Goetz A, Gaul N, Choudhry AE, Alsaid H, Jucker BM, Axten JM, Kumar R., Cancer Res. 73(6), 2013
PMID: 23333938
Drugging the 'undruggable' cancer targets.
Dang CV, Reddy EP, Shokat KM, Soucek L., Nat. Rev. Cancer 17(8), 2017
PMID: 28643779
Pharmacological targeting of MYC-regulated IRE1/XBP1 pathway suppresses MYC-driven breast cancer.
Zhao N, Cao J, Xu L, Tang Q, Dobrolecki LE, Lv X, Talukdar M, Lu Y, Wang X, Hu DZ, Shi Q, Xiang Y, Wang Y, Liu X, Bu W, Jiang Y, Li M, Gong Y, Sun Z, Ying H, Yuan B, Lin X, Feng XH, Hartig SM, Li F, Shen H, Chen Y, Han L, Zeng Q, Patterson JB, Kaipparettu BA, Putluri N, Sicheri F, Rosen JM, Lewis MT, Chen X., J. Clin. Invest. 128(4), 2018
PMID: 29480818
HES6 drives a critical AR transcriptional programme to induce castration-resistant prostate cancer through activation of an E2F1-mediated cell cycle network.
Ramos-Montoya A, Lamb AD, Russell R, Carroll T, Jurmeister S, Galeano-Dalmau N, Massie CE, Boren J, Bon H, Theodorou V, Vias M, Shaw GL, Sharma NL, Ross-Adams H, Scott HE, Vowler SL, Howat WJ, Warren AY, Wooster RF, Mills IG, Neal DE., EMBO Mol Med 6(5), 2014
PMID: 24737870
Endoplasmic reticulum stress in malignancy.
Clarke HJ, Chambers JE, Liniker E, Marciniak SJ., Cancer Cell 25(5), 2014
PMID: 24823636
The Interaction of Myc with Miz1 Defines Medulloblastoma Subgroup Identity.
Vo BT, Wolf E, Kawauchi D, Gebhardt A, Rehg JE, Finkelstein D, Walz S, Murphy BL, Youn YH, Han YG, Eilers M, Roussel MF., Cancer Cell 29(1), 2016
PMID: 26766587
A SUMO-regulated activation function controls synergy of c-Myb through a repressor-activator switch leading to differential p300 recruitment.
Molvaersmyr AK, Saether T, Gilfillan S, Lorenzo PI, Kvaloy H, Matre V, Gabrielsen OS., Nucleic Acids Res. 38(15), 2010
PMID: 20385574
The search for synergy: a critical review from a response surface perspective.
Greco WR, Bravo G, Parsons JC., Pharmacol. Rev. 47(2), 1995
PMID: 7568331
Adaptation of the secretory pathway in cancer through IRE1 signaling.
Lhomond S, Pallares N, Barroso K, Schmit K, Dejeans N, Fazli H, Taouji S, Patterson JB, Chevet E., Methods Mol. Biol. 1292(), 2015
PMID: 25804756
STAR: ultrafast universal RNA-seq aligner.
Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR., Bioinformatics 29(1), 2012
PMID: 23104886
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2.
Love MI, Huber W, Anders S., Genome Biol. 15(12), 2014
PMID: 25516281
Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators.
Hieronymus H, Lamb J, Ross KN, Peng XP, Clement C, Rodina A, Nieto M, Du J, Stegmaier K, Raj SM, Maloney KN, Clardy J, Hahn WC, Chiosis G, Golub TR., Cancer Cell 10(4), 2006
PMID: 17010675
Small molecule proteostasis regulators that reprogram the ER to reduce extracellular protein aggregation.
Plate L, Cooley CB, Chen JJ, Paxman RJ, Gallagher CM, Madoux F, Genereux JC, Dobbs W, Garza D, Spicer TP, Scampavia L, Brown SJ, Rosen H, Powers ET, Walter P, Hodder P, Wiseman RL, Kelly JW., Elife 5(), 2016
PMID: 27435961
Integrative clinical genomics of advanced prostate cancer.
Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng FY, Tomlins SA, Cooney KA, Smith DC, Brennan C, Siddiqui J, Mehra R, Chen Y, Rathkopf DE, Morris MJ, Solomon SB, Durack JC, Reuter VE, Gopalan A, Gao J, Loda M, Lis RT, Bowden M, Balk SP, Gaviola G, Sougnez C, Gupta M, Yu EY, Mostaghel EA, Cheng HH, Mulcahy H, True LD, Plymate SR, Dvinge H, Ferraldeschi R, Flohr P, Miranda S, Zafeiriou Z, Tunariu N, Mateo J, Perez-Lopez R, Demichelis F, Robinson BD, Schiffman M, Nanus DM, Tagawa ST, Sigaras A, Eng KW, Elemento O, Sboner A, Heath EI, Scher HI, Pienta KJ, Kantoff P, de Bono JS, Rubin MA, Nelson PS, Garraway LA, Sawyers CL, Chinnaiyan AM., Cell 161(5), 2015
PMID: 26000489
Integrative genomic profiling of human prostate cancer.
Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, Socci ND, Lash AE, Heguy A, Eastham JA, Scher HI, Reuter VE, Scardino PT, Sander C, Sawyers CL, Gerald WL., Cancer Cell 18(1), 2010
PMID: 20579941
The Molecular Taxonomy of Primary Prostate Cancer.
Cancer Genome Atlas Research Network, Abeshouse A, Ahn J, Akbani R, Ally A, Amin S, Andry CD, Annala M, Aprikian A, Armenia J, Arora A, Auman JT, Balasundaram M, Balu S, Barbieri CE, Bauer T, Benz CC, Bergeron A, Beroukhim R, Berrios M, Bivol A, Bodenheimer T, Boice L, Bootwalla MS, Borges dos Reis R, Boutros PC, Bowen J, Bowlby R, Boyd J, Bradley RK, Breggia A, Brimo F, Bristow CA, Brooks D, Broom BM, Bryce AH, Bubley G, Burks E, Butterfield YS, Button M, Canes D, Carlotti CG, Carlsen R, Carmel M, Carroll PR, Carter SL, Cartun R, Carver BS, Chan JM, Chang MT, Chen Y, Cherniack AD, Chevalier S, Chin L, Cho J, Chu A, Chuah E, Chudamani S, Cibulskis K, Ciriello G, Clarke A, Cooperberg MR, Corcoran NM, Costello AJ, Cowan J, Crain D, Curley E, David K, Demchok JA, Demichelis F, Dhalla N, Dhir R, Doueik A, Drake B, Dvinge H, Dyakova N, Felau I, Ferguson ML, Frazer S, Freedland S, Fu Y, Gabriel SB, Gao J, Gardner J, Gastier-Foster JM, Gehlenborg N, Gerken M, Gerstein MB, Getz G, Godwin AK, Gopalan A, Graefen M, Graim K, Gribbin T, Guin R, Gupta M, Hadjipanayis A, Haider S, Hamel L, Hayes DN, Heiman DI, Hess J, Hoadley KA, Holbrook AH, Holt RA, Holway A, Hovens CM, Hoyle AP, Huang M, Hutter CM, Ittmann M, Iype L, Jefferys SR, Jones CD, Jones SJ, Juhl H, Kahles A, Kane CJ, Kasaian K, Kerger M, Khurana E, Kim J, Klein RJ, Kucherlapati R, Lacombe L, Ladanyi M, Lai PH, Laird PW, Lander ES, Latour M, Lawrence MS, Lau K, LeBien T, Lee D, Lee S, Lehmann KV, Leraas KM, Leshchiner I, Leung R, Libertino JA, Lichtenberg TM, Lin P, Linehan WM, Ling S, Lippman SM, Liu J, Liu W, Lochovsky L, Loda M, Logothetis C, Lolla L, Longacre T, Lu Y, Luo J, Ma Y, Mahadeshwar HS, Mallery D, Mariamidze A, Marra MA, Mayo M, McCall S, McKercher G, Meng S, Mes-Masson AM, Merino MJ, Meyerson M, Mieczkowski PA, Mills GB, Mills Shaw KR, Minner S, Moinzadeh A, Moore RA, Morris S, Morrison C, Mose LE, Mungall AJ, Murray BA, Myers JB, Naresh R, Nelson J, Nelson MA, Nelson PS, Newton Y, Noble MS, Noushmehr H, Nykter M, Pantazi A, Parfenov M, Park PJ, Parker JS, Paulauskis J, Penny R, Perou CM, Piche A, Pihl T, Pinto PA, Prandi D, Protopopov A, Ramirez NC, Rao A, Rathmell WK, Ratsch G, Ren X, Reuter VE, Reynolds SM, Rhie SK, Rieger-Christ K, Roach J, Robertson AG, Robinson B, Rubin MA, Saad F, Sadeghi S, Saksena G, Saller C, Salner A, Sanchez-Vega F, Sander C, Sandusky G, Sauter G, Sboner A, Scardino PT, Scarlata E, Schein JE, Schlomm T, Schmidt LS, Schultz N, Schumacher SE, Seidman J, Neder L, Seth S, Sharp A, Shelton C, Shelton T, Shen H, Shen R, Sherman M, Sheth M, Shi Y, Shih J, Shmulevich I, Simko J, Simon R, Simons JV, Sipahimalani P, Skelly T, Sofia HJ, Soloway MG, Song X, Sorcini A, Sougnez C, Stepa S, Stewart C, Stewart J, Stuart JM, Sullivan TB, Sun C, Sun H, Tam A, Tan D, Tang J, Tarnuzzer R, Tarvin K, Taylor BS, Teebagy P, Tenggara I, Tetu B, Tewari A, Thiessen N, Thompson T, Thorne LB, Tirapelli DP, Tomlins SA, Trevisan FA, Troncoso P, True LD, Tsourlakis MC, Tyekucheva S, Van Allen E, Van Den Berg DJ, Veluvolu U, Verhaak R, Vocke CD, Voet D, Wan Y, Wang Q, Wang W, Wang Z, Weinhold N, Weinstein JN, Weisenberger DJ, Wilkerson MD, Wise L, Witte J, Wu CC, Wu J, Wu Y, Xu AW, Yadav SS, Yang L, Yang L, Yau C, Ye H, Yena P, Zeng T, Zenklusen JC, Zhang H, Zhang J, Zhang J, Zhang W, Zhong Y, Zhu K, Zmuda E., Cell 163(4), 2015
PMID: 26544944
DESNT: A Poor Prognosis Category of Human Prostate Cancer.
Luca BA, Brewer DS, Edwards DR, Edwards S, Whitaker HC, Merson S, Dennis N, Cooper RA, Hazell S, Warren AY; CancerMap Group, Eeles R, Lynch AG, Ross-Adams H, Lamb AD, Neal DE, Sethia K, Mills RD, Ball RY, Curley H, Clark J, Moulton V, Cooper CS., Eur Urol Focus 4(6), 2017
PMID: 28753852
The transcriptional program of a human B cell line in response to Myc.
Schuhmacher M, Kohlhuber F, Holzel M, Kaiser C, Burtscher H, Jarsch M, Bornkamm GW, Laux G, Polack A, Weidle UH, Eick D., Nucleic Acids Res. 29(2), 2001
PMID: 11139609
Global transcriptome analysis of formalin-fixed prostate cancer specimens identifies biomarkers of disease recurrence.
Long Q, Xu J, Osunkoya AO, Sannigrahi S, Johnson BA, Zhou W, Gillespie T, Park JY, Nam RK, Sugar L, Stanimirovic A, Seth AK, Petros JA, Moreno CS., Cancer Res. 74(12), 2014
PMID: 24713434
Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study.
Ross-Adams H, Lamb AD, Dunning MJ, Halim S, Lindberg J, Massie CM, Egevad LA, Russell R, Ramos-Montoya A, Vowler SL, Sharma NL, Kay J, Whitaker H, Clark J, Hurst R, Gnanapragasam VJ, Shah NC, Warren AY, Cooper CS, Lynch AG, Stark R, Mills IG, Gronberg H, Neal DE; CamCaP Study Group., EBioMedicine 2(9), 2015
PMID: 26501111
Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process.
Chandran UR, Ma C, Dhir R, Bisceglia M, Lyons-Weiler M, Liang W, Michalopoulos G, Becich M, Monzon FA., BMC Cancer 7(), 2007
PMID: 17430594
Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy.
Yu YP, Landsittel D, Jing L, Nelson J, Ren B, Liu L, McDonald C, Thomas R, Dhir R, Finkelstein S, Michalopoulos G, Becich M, Luo JH., J. Clin. Oncol. 22(14), 2004
PMID: 15254046
Molecular sampling of prostate cancer: a dilemma for predicting disease progression.
Sboner A, Demichelis F, Calza S, Pawitan Y, Setlur SR, Hoshida Y, Perner S, Adami HO, Fall K, Mucci LA, Kantoff PW, Stampfer M, Andersson SO, Varenhorst E, Johansson JE, Gerstein MB, Golub TR, Rubin MA, Andren O., BMC Med Genomics 3(), 2010
PMID: 20233430
The mutational landscape of lethal castration-resistant prostate cancer.
Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC, Asangani IA, Ateeq B, Chun SY, Siddiqui J, Sam L, Anstett M, Mehra R, Prensner JR, Palanisamy N, Ryslik GA, Vandin F, Raphael BJ, Kunju LP, Rhodes DR, Pienta KJ, Chinnaiyan AM, Tomlins SA., Nature 487(7406), 2012
PMID: 22722839
Endoplasmic reticulum stress-activated cell reprogramming in oncogenesis.
Chevet E, Hetz C, Samali A., Cancer Discov 5(6), 2015
PMID: 25977222
Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer.
Kumar A, Coleman I, Morrissey C, Zhang X, True LD, Gulati R, Etzioni R, Bolouri H, Montgomery B, White T, Lucas JM, Brown LG, Dumpit RF, DeSarkar N, Higano C, Yu EY, Coleman R, Schultz N, Fang M, Lange PH, Shendure J, Vessella RL, Nelson PS., Nat. Med. 22(4), 2016
PMID: 26928463
Microarray analysis of hepatic gene expression identifies new genes involved in steatotic liver.
Guillen N, Navarro MA, Arnal C, Noone E, Arbones-Mainar JM, Acin S, Surra JC, Muniesa P, Roche HM, Osada J., Physiol. Genomics 37(3), 2009
PMID: 19258494
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP., Proc. Natl. Acad. Sci. U.S.A. 102(43), 2005
PMID: 16199517
PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes.
Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstrale M, Laurila E, Houstis N, Daly MJ, Patterson N, Mesirov JP, Golub TR, Tamayo P, Spiegelman B, Lander ES, Hirschhorn JN, Altshuler D, Groop LC., Nat. Genet. 34(3), 2003
PMID: 12808457
Targeting the unfolded protein response in disease.
Hetz C, Chevet E, Harding HP., Nat Rev Drug Discov 12(9), 2013
PMID: 23989796
Prostate cancer and the unfolded protein response.
Storm M, Sheng X, Arnoldussen YJ, Saatcioglu F., Oncotarget 7(33), 2016
PMID: 27303918
Cancer Statistics, 2017.
Siegel RL, Miller KD, Jemal A., CA Cancer J Clin 67(1), 2017
PMID: 28055103
Prostate cancer.
Attard G, Parker C, Eeles RA, Schroder F, Tomlins SA, Tannock I, Drake CG, de Bono JS., Lancet 387(10013), 2015
PMID: 26074382

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®

Quellen

PMID: 30679434
PubMed | Europe PMC

Suchen in

Google Scholar